- Home
- NABL vs CNTA Comparison
NABL vs CNTA Comparison
Compare NABL & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NABL
- CNTA
- Stock Information
- Founded
- NABL 2000
- CNTA 2020
- Country
- NABL United States
- CNTA United Kingdom
- Employees
- NABL N/A
- CNTA N/A
- Industry
- NABL Computer Software: Prepackaged Software
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- NABL Technology
- CNTA Health Care
- Exchange
- NABL Nasdaq
- CNTA Nasdaq
- Market Cap
- NABL 1.2B
- CNTA 1.8B
- IPO Year
- NABL N/A
- CNTA 2021
- Fundamental
- Price
- NABL $7.54
- CNTA $12.52
- Analyst Decision
- NABL Buy
- CNTA Strong Buy
- Analyst Count
- NABL 4
- CNTA 10
- Target Price
- NABL $9.38
- CNTA $26.11
- AVG Volume (30 Days)
- NABL 1.0M
- CNTA 663.9K
- Earning Date
- NABL 05-08-2025
- CNTA 05-20-2025
- Dividend Yield
- NABL N/A
- CNTA N/A
- EPS Growth
- NABL N/A
- CNTA N/A
- EPS
- NABL 0.08
- CNTA N/A
- Revenue
- NABL $470,595,000.00
- CNTA N/A
- Revenue This Year
- NABL $7.38
- CNTA N/A
- Revenue Next Year
- NABL $9.67
- CNTA N/A
- P/E Ratio
- NABL $94.58
- CNTA N/A
- Revenue Growth
- NABL 7.98
- CNTA N/A
- 52 Week Low
- NABL $6.07
- CNTA $7.75
- 52 Week High
- NABL $15.49
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- NABL 61.38
- CNTA 37.13
- Support Level
- NABL $7.07
- CNTA $11.82
- Resistance Level
- NABL $7.32
- CNTA $14.39
- Average True Range (ATR)
- NABL 0.22
- CNTA 0.76
- MACD
- NABL 0.12
- CNTA -0.01
- Stochastic Oscillator
- NABL 77.93
- CNTA 4.28
About NABL N-able Inc.
N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. The company also has a presence in the United Kingdom and all other International regions.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.